Year-end Sale % OFF 
Abstract
BackgroundThe immune response has been proposed to be an important factor in determining patient outcome in colorectal cancer (CRC). Previous studies have concentrated on characterizing T cell populations in the primary tumour where T cells with regulatory effect (Foxp3+ Tregs) have been identified as both enhancing and diminishing anti-tumour immune responses. No previous studies have characterized the T cell response in the regional lymph nodes in CRC.MethodsImmunohistochemistry was used to analyse CD4, CD8 or Foxp3+ T cell populations in the regional lymph nodes of patients with stage II CRC (n = 31), with (n = 13) or without (n = 18) cancer recurrence after 5 years of follow up, to determine if the priming environment for anti-tumour immunity was associated with clinical outcome.ResultsThe proportions of CD4, CD8 or Foxp3+ cells in the lymph nodes varied widely between and within patients, and there was no association between T cell populations and cancer recurrence or other clinicopathological characteristics.ConclusionsThese data indicate that frequency of these T cell subsets in lymph nodes may not be a useful tool for predicting patient outcome.
Highlights
The immune response has been proposed to be an important factor in determining patient outcome in colorectal cancer (CRC)
In this study we examined the lymph nodes of Stage II colorectal cancer patients to identify CD4+, CD8+ and Foxp3+ cell populations and correlated these with patient outcome, alone, and in combination with other clinico-pathological variables
In this paper, we have described the analysis of T cell populations in the lymph nodes of Stage II colorectal cancer patients
Summary
The immune response has been proposed to be an important factor in determining patient outcome in colorectal cancer (CRC). Previous studies have concentrated on characterizing T cell populations in the primary tumour where T cells with regulatory effect (Foxp3+ Tregs) have been identified as both enhancing and diminishing anti-tumour immune responses. No previous studies have characterized the T cell response in the regional lymph nodes in CRC. Approximately 25% of patients with disease localised to the primary site (UICC Stage I and II) relapse after surgery and may have benefited from adjuvant therapy [2], whereas 25% of patients with regional lymph node metastases (UICC Stage III) are cured by surgery alone [3]. It has become clear that T cells in the tumour are positively associated with good patient prognosis [10,11] in colorectal cancer. CD4 or CD8+ T cells expressing IFNg, or the IFNg inducing transcription factor Tbet, are the cells most likely involved at the tumour site [12,13]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Experimental & Clinical Cancer Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
